Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?

Expert Opinion on Investigational Drugs

Volumn 12, Issue 8, 2003, Pages 1429-1432

  Doggrell, Sheila A ^a   Wanstall, Janet C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

BCEAB; Cardiomyopathy; Chymase inhibition; Intimal hyperplasia; NK3201

Indexed keywords

2 (5 FORMYLAMINO 6 OXO 2 PHENYL 1,6 DIHYDROPYRIMIDINE 1 YL) N [[3,4 DIOXO 1 PHENYL 7 (2 PYRIDYLOXY)] 2 HEPTYL]ACETAMIDE; 4 [1 [(BIS 4 METHYLPHENYL)METHYL]CARBAMOYL] 3 [(2 ETHOXYBENZYL) 4 OXOAZETIDINE 2 YLOXYL]BENZOIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; PLACEBO; PROCOLLAGEN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLLAGEN DEGRADATION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HEART MUSCLE FIBROSIS; HORMONE SYNTHESIS; HUMAN; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PROTEIN INDUCTION; RESTENOSIS; SECRETORY GRANULE;

ACETAMIDES; ANIMALS; AZETIDINES; BENZOIC ACIDS; CARDIOVASCULAR DISEASES; CHYMASES; DISEASE MODELS, ANIMAL; HUMANS; PYRIMIDINES; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; TUNICA INTIMA;

EID: 0041633492     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.8.1429     Document Type: Article

References (12)

1. TAKAI S, SAKONJO H, FUKUDA K et al.: A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl-N-[{3, 4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl] acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J. Pharmacol. Exp. Ther. (2003) 304:841-844.
2. TAKAI S, JIN D, SAKAGUCHI MJ et al.: A novel chymase inhibitor, 4-[1-{[bis-4-methyl-phenyl)-methyl]-carbamoyl}-3-(2-ethoxy-benzy) -4-oxo-azetidine-2-yloxyl]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J. Pharmacol., Exp. Ther. (2003) 305:17-23.
3. TAIPALE J, LOHI J, SAARINEN J, KOVANEN PT, KESKI-OJA J: Human mast cell chymase and leukocyte elastase release latent transforming factor-β1 from the extracellular matrix of cultured human epithelia and endothelial cells. J. Biol. Chem. (1995) 270:4689-4696.
4. KOFFORD MW SCHWARTZ LB, SCHECHTER NM et al.: Cleavage of Type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem (1997) 272:7127-7131.
5. UEHARA Y, URATA H, SASAGURI M et a.l: Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension (2000) 35:55-60.
6. TAKAI S, JIN D, NISHIMOTO M et al.: Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci. (2001) 69:1725-1732.
7. PATELLA V, MARINO I, ARBUSTINI E et al.: Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation (1998) 97:971-978.
8. LI RK, LI G, MICKLE DA et al.: Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation (1997) 96:874-881.
9. PUN KK, ARNAUD CD, NISSENSION RA. Parathyroid hormone receptors in human dermal fibroblasts: structure and functional characterization. J. Bone Miner. Res. (1988) 8:453-460.
10. NISHIMOTO M, TAKAI S, KIM S et al.: Significance of chymase-dependent angiotensin II forming pathway in the development of vascular proliferation. Ciresdatim (2001) 104:1274-1279.
11. TAMAI H, KATOH K, YAMAGUCHI T et al.: The impact of tranilast on restenosis after coronary angioplasty: The Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am. Heart J. (2002) 143:506-513.
12. HOLMES DR, SAVAGE M, LABLANCHE J-M et al.: Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2002) 106:1243-1250.